Neuroscience Research Group, Medical Research Institute, Faculty of Medicine, University of Antioquia (UdeA), Medellín, Antioquia, Colombia.
Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA; Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA.
Parkinsonism Relat Disord. 2019 Jun;63:204-208. doi: 10.1016/j.parkreldis.2019.01.030. Epub 2019 Feb 4.
Mutations in the glucocerebrosidase (GBA) gene are an important risk factor for Parkinson's disease (PD). However, most GBA genetic studies in PD have been performed in patients of European origin and very few data are available in other populations.
We sequenced the entire GBA coding region in 602 PD patients and 319 controls from Colombia and Peru enrolled as part of the Latin American Research Consortium on the Genetics of Parkinson's disease (LARGE-PD).
We observed a significantly higher proportion of GBA mutation carriers in patients compared to healthy controls (5.5% vs 1.6%; OR = 4.3, p = 0.004). Interestingly, the frequency of mutations in Colombian patients (9.9%) was more than two-fold greater than in Peruvian patients (4.2%) and other European-derived populations reported in the literature (4-5%). This was primarily due to the presence of a population-specific mutation (p.K198E) found only in the Colombian cohort. We also observed that the age at onset was significantly earlier in GBA carriers when compared to non-carriers (47.1 ± 14.2 y vs. 55.9 ± 14.2 y; p = 0.0004).
These findings suggest that GBA mutations are strongly associated with PD risk and earlier age at onset in Peru and Colombia. The high frequency of GBA carriers among Colombian PD patients (∼10%) makes this population especially well-suited for novel therapeutic approaches that target GBA-related PD.
葡萄糖脑苷脂酶 (GBA) 基因突变是帕金森病 (PD) 的一个重要风险因素。然而,大多数 GBA 基因研究都是在欧洲起源的 PD 患者中进行的,其他人群的数据非常有限。
我们对来自哥伦比亚和秘鲁的 602 名 PD 患者和 319 名对照进行了 GBA 基因全编码区测序,这些患者和对照是拉丁美洲帕金森病遗传学研究联盟(LARGE-PD)的一部分。
我们观察到患者中 GBA 突变携带者的比例明显高于健康对照者(5.5%比 1.6%;OR=4.3,p=0.004)。有趣的是,哥伦比亚患者的突变频率(9.9%)是秘鲁患者(4.2%)和文献中报道的其他欧洲衍生人群的两倍多(4-5%)。这主要是由于在哥伦比亚队列中发现了一种特定于人群的突变(p.K198E)。我们还观察到,与非携带者相比,GBA 携带者的发病年龄明显更早(47.1±14.2 岁比 55.9±14.2 岁;p=0.0004)。
这些发现表明,GBA 突变与 PD 风险和发病年龄早有关,在秘鲁和哥伦比亚尤为明显。在哥伦比亚 PD 患者中,GBA 携带者的高频率(约 10%)使该人群特别适合针对 GBA 相关 PD 的新型治疗方法。